Antibiotic Accelerator From BARDA Nears Investment Stage
This article was originally published in The Pink Sheet Daily
Executive Summary
Federal funding could pay to help early antibiotic discovery efforts with 'fragile' pipeline still struggling.
You may also be interested in...
FDA Worries About Off-Label Use, Stewardship With Limited-Population Approval Pathway
FDA asks groups how it can help ensure prescribing is limited for products approved under proposed new pathway, but several say, other than labeling, it may be out of the agency’s hands.
US FDA Oncology, Device Centers Developing Public Diagnostic Standards
Pilot program would get around the ‘one drug, one test’ policy, which has created intellectual property issues.
AAM CEO Leonard Departs After Two Years, Creating Another Trade Group Searching For New Leader
David Gaugh, AAM’s executive VP of sciences and regulatory affairs, was named the interim CEO, making him the fourth person to run the association since February 2020.